Biocon Limited

rs,

, 2025 To, The Secretary BSE Limited Department of Corporate Services, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523 Dear Sir/Madam, To, The Secretary National

INR 300 crore

ment with Edelweiss. Full benefit of debt reduction to be visible from FY27 with annual savings of ~INR 300 crores in interest costs Delivered on product launch commitment with successful launches of bUstekinumab

1 %

Q2 FY26 In ₹ Cr Generics Biosimilars CRDMO Revenue from Operations Total Revenue Core EBITDA1 % Margin R&D (Net) % of Revenue (Ex. Syngene) EBITDA % Margin Profit Before Tax (Before except

32%

rket shares across products, with uptick in Ogivri and Abvemy market shares % of Total Revenue 32% 32% 31% • Continued bUstekinumab across seven markets to advance our immunology franchise

31%

s across products, with uptick in Ogivri and Abvemy market shares % of Total Revenue 32% 32% 31% • Continued bUstekinumab across seven markets to advance our immunology franchise, launch

7%

franchise, launching R & D 180 138 134 30 34 Emerging Markets Highlights % of Revenue 7% 6% 5% • Strong momentum driven by growth in self-led, high impact markets EBITDA 669 469 66

6%

anchise, launching R & D 180 138 134 30 34 Emerging Markets Highlights % of Revenue 7% 6% 5% • Strong momentum driven by growth in self-led, high impact markets EBITDA 669 469 662 4

5%

ise, launching R & D 180 138 134 30 34 Emerging Markets Highlights % of Revenue 7% 6% 5% • Strong momentum driven by growth in self-led, high impact markets EBITDA 669 469 662 43 1

25%

by growth in self-led, high impact markets EBITDA 669 469 662 43 1 Financial Performance • 25% YoY growth driven by robust product demand across markets % of Revenue 25% 21% 27% • Over 40%

21%

l Performance • 25% YoY growth driven by robust product demand across markets % of Revenue 25% 21% 27% • Over 40% YoY growth in EBITDA • EBITDA Margin at 25%, a 400bps YoY expansion reflecting im

27%

formance • 25% YoY growth driven by robust product demand across markets % of Revenue 25% 21% 27% • Over 40% YoY growth in EBITDA • EBITDA Margin at 25%, a 400bps YoY expansion reflecting improve

40%

25% YoY growth driven by robust product demand across markets % of Revenue 25% 21% 27% • Over 40% YoY growth in EBITDA • EBITDA Margin at 25%, a 400bps YoY expansion reflecting improved operating

“It also expanded its clinical trials footprint to several countries strengthening global trial execution capabilities through strategic partnerships with well-established CROs in these regions Syngene will expand its biologics facility in Bengaluru with a GMP integrated, end-to-end bioconjugation suite manufacturing of ADCs.”

Financial Performance

1

Financial Performance

• • R&D investments at 9% of revenue, with continued progress across 24% YoY & 11% sequential revenue growth our GLP-1 and injectables portfolio • EBITDA improved over last year and the previous quarter, driven by higher revenues Core EBITDA 96 98 63 (1) % of Total Revenue 12% 15% 9% R & D 71 67 70 6 2 % of Revenue 9% 11% 11% EBITDA % of Total Revenue 43 5% 36 1 21 >100 6% 0% 11 53 CRDMO CRDMO: Q2 FY26 Business Performance update Performance in Q2 was in line with plan with revenue up 2% YOY; 4% sequentially In ₹ Cr Q2 FY26 Q2 FY25 Q1 FY26 YoY% QoQ% Quarterly performance driven by revenue growth from research services, offsetting the expected inventory correction in biologics manufacturing Segment Revenue 911 891 875 2 4 First-half results in line with expectation; maintains its FY26 guidance Syngene continues to strengthen capabilities and expand its global footprint Reported EBITDA % of Total Revenue 215 261 224 (18) (4) 23% 29% 25% • • • Syngene secured its first global phase III cl